Highlights {#S1}
==========

1.  Conducted an integrative analysis to prioritize the CAD potential causal genes by using eight computational methods.

2.  Identified 55 high-confidence causal genes for CAD, among which 15 genes ranked the highest priority.

3.  Plausible causal genes were enriched in lipid metabolic and extracellular region.

Introduction {#S2}
============

With the number of all-age deaths closing to nine million in 2017, CAD is the leading cause of mortality worldwide ([@B15]). Parallel to the high prevalence and vast number of deaths, CAD also places a crushing economic burden. According to the recent American Heart Association report, the medical costs and productivity losses of CVD are expected to grow from \$555 billion in 2015 to \$1.1 trillion in 2035 ([@B12]; [@B2]). Although CAD has become a major concern in global public health, there still a long way to fully understand the etiology of CAD before getting it under control.

In addition to lifestyle risk factors such as physical inactivity, unbalanced diet, smoking, alcohol, and obesity ([@B38]), genetic factors also play a pivotal role in CAD susceptibility ([@B44]). Family and twin studies have demonstrated a strong genetic component of CAD, with heritability estimated between 40 and 60% ([@B37]; [@B27]). To unravel the genetic underpinnings of CAD, multiple large-scale genetic studies have been performed. During the past decade, GWASs have identified more than 150 genetic loci at the commonly accepted genome-wide statistical significant threshold of *P* \< 5 × 10^--8^ to account for multiple testing ([@B21]; [@B28]; [@B46]; [@B65]). Considering the polygenic nature of CAD, more variants are expected to be identified in the near future owing to the rapid increase in sample size ([@B71]). However, the success of GWAS has not been fully translated into an ability to find biological mechanisms and therapeutic targets behind these associations ([@B58]; [@B44]).

There exist some difficulties in localizing the causal genes directly from the GWAS results. First, the lead variant identified by GWAS represents a set of variants in LD that usually spans large genomic regions ([@B14]). The complicated LD between SNPs and causative mutations is a major barrier to pinpoint the plausible causal genes. Second, the genes in the closest physical proximity to the top associated variants may be not the causal genes because of gene regulation ([@B59]). The causal variants mediate the effect on disease risk through either a local effect on gene within the locus or action at a distance on a more remote gene. Therefore, the complexity of LD structure and distal regulation impedes our ability to identify causal genes from GWAS results. To address this issue, many GWAS-based computational methods aiming to prioritize the most likely causal genes have been developed ([@B51]; [@B20]; [@B17]; [@B50]; [@B62]; [@B19]; [@B74]; [@B57]). For example, *Sherlock*, *SMR*, and *TWAS* prioritize causal genes by combining GWAS and eQTL data; *DAPPLE* integrates GWAS data with PPI network to identify potential causal genes; *DEPICT* identifies causal genes through integrating GWAS and predicts gene functions; and *prix fixe*, *NetWAS*, and *GWAB* predict causal genes using co-function network, tissue-specific network, and human functional gene network, respectively.

In this study, we systematically prioritized the potential causal genes for CAD through eight cutting-edge methods (*Sherlock*, *SMR*, *DAPPLE*, *NetWAS*, *prix fixe*, *GWAB*, *DEPICT*, and *TWAS*), which are complementary with each other. Candidate causal genes were further characterized by pathway enrichment analysis, tissue-specific enrichment analysis, and pathway crosstalk analysis ([Figure 1](#F1){ref-type="fig"}). This landscape of potential causal genes could provide information and evidence to elucidate the genetic mechanisms underlying CAD.

![Overview of study pipelines.](fgene-11-00320-g001){#F1}

Materials and Methods {#S3}
=====================

Genome-Wide Association Study Data of Coronary Artery Disease {#S3.SS1}
-------------------------------------------------------------

We used summary statistics from a large-scale CAD GWAS in our study ([@B46]). In brief, [@B46] performed a genome-wide association meta-analysis of the United Kingdom Biobank data with two published datasets (CARDIoGRAMplusC4D 1000 Genomes-imputed GWAS ([@B47]) and MIGen/CARDIoGRAM Exome chip study ([@B60]; [@B68]). The study comprised a total of 71,602 CAD cases and 260,875 controls and identified 304 independent variants, clustering 243 loci, associated with CAD at 5% FDR. More detailed information regarding sample recruitment, genotyping, quality control, and statistical analysis in provided in the original study ([@B46]).

Blood Expression Quantitative Trait Locus Data {#S3.SS2}
----------------------------------------------

We used eQTL summary data from the Consortium for the Architecture of Gene Expression (CAGE, *n* = 2,765 in peripheral blood) and the GTEx Consortium v7 release (*n* = 369 from whole blood). Briefly, [@B34] performed this analysis of 2,765 samples from peripheral blood, with gene expression data observed from Illumina gene expression arrays (38,624 gene expression probes) and SNP genotype data imputed to the 1000 Genomes Phase 1 Version 3 reference panel (∼8 million SNPs). Information about tissue collection, genotyping, RNA quantification, and statistical analysis can be found in the original study of Lloyd et al. (2017). The GTEx project ([@B18]) contained samples from 44 healthy tissues of 20- to 70-year-old human postmortem donors. For GTEx eQTL data (v7), whole blood tissues of 369 individuals were used, and gene expression levels measured by RNA-seq. SNP genotyping was performed using the Illumina OMNI SNP Arrays.

Prioritization of Coronary Artery Disease Candidate Causal Genes {#S3.SS3}
----------------------------------------------------------------

### Sherlock Integrative Analysis {#S3.SS3.SSS1}

Based on the assumption that the expression change of a specific gene may contribute to CAD risk, we used *Sherlock* integrative analysis method to integrate SNP associations from CARDIoGRAMplusC4D consortium and blood eQTL from GTEx ([@B20]). *Sherlock* utilizes a Bayesian statistical framework to infer causal genes. It calculates the logarithm of Bayes factor (LBF) for each gene to represent the probability of association between specific gene and CAD. Bonferroni correction was used to correct the *P* value of genes identified by *Sherlock* integrative analysis. The corrected threshold of *P* value is 8.7 × 10^--6^ (there were 5,747 genes in the eQTL test).

### Summary Data-Based Mendelian Randomization Analysis {#S3.SS3.SSS2}

Similar to *Sherlock*, *SMR* performs integrative analysis through integrating genetic associations from GWAS and eQTL data from CAGE ([@B74]). Additionally, *SMR* uses *HEIDI* test to distinguish pleiotropy from linkage. Genes were considered as plausible causal gene only if they passed both *SMR* and *HEIDI* tests. The genome-wide significant threshold was defined as *P*~SMR~ \< 5.24 × 10^--6^, because we retained 9,538 gene expression probes from the CAGE eQTL analysis.

### Disease Association Protein--Protein Link Evaluator {#S3.SS3.SSS3}

Based on the "guilt by association" principle, many previous studies incorporated PPI network into GWAS analysis in order to prioritize candidate genes ([@B24]; [@B25]), and *DAPPLE* is one of the popular approaches ([@B51]). It requires a set of association loci as input and prioritizes genes according to connectivity in the PPI network. Genes with a corrected *P* value less than 0.05 will be considered as potential causal genes.

### Network-Wide Association Study {#S3.SS3.SSS4}

Network-Wide Association Study is a machine learning method that combines gene-level association with the tissue-specific interaction network ([@B17]). The network was built using 14,000 publications and low-throughput tissue-specific expression data, which could describe the gene--gene functional interactions within a specific tissue. In this study, we used VEGAS2 ([@B41]) to convert SNP-based summary statistics into gene-based *P* values. We prioritize the genes in a network built from liver tissue and set 0.05 as *P* value threshold, which implied that genes with *P* value below this cutoff were treated as positive in *NetWAS*.

### Prix Fixe Analysis {#S3.SS3.SSS5}

The *prix fixe* strategy uses co-function networks to prioritize genes from multiple disease-associated loci ([@B62]). It identifies genes by evaluating the significance of combinations of genes, with one gene from each GWAS candidate locus, in a gene network. In this study, the top 100 index SNPs from CAD GWAS were used as input for *prix fixe* (as *prix fixe* only accepts a maximum of 100 SNPs as input). By averaging the importance measurements, *prix fixe* (PF) score was obtained to prioritize candidate genes.

### Genome-Wide Association Boosting {#S3.SS3.SSS6}

Holding the view that the genes associated with a disease tend to be functionally together, *GWAB* prioritizes candidate disease genes by integrating the GWAS data and human functional gene network ([@B57]). Unlike other network-based approach, *GWAB* has an advantage that it integrates complementary information from both population-based approach and molecular profiling approach to identify disease-associated genes. Therefore, it can make the best of information identified from functional experiments apart from the statistical association from GWAS. [@B57] used GWAS data from [@B54] as input and referenced genes from three disease gene databases (OMIM, DO, and CADgeneDB) as benchmark to predict for disease-associated genes. We therefore included Jung Eun Shim's results into our study.

### Transcriptome-Wide Association Studies {#S3.SS3.SSS7}

The *TWAS* ([@B19]) is a powerful strategy that integrates SNP--expression correlation, GWAS summary statistics, and LD reference panels to identify genes whose *cis*-regulated expression is associated with disease risk. This method can be conceptualized as having imputed expression data for all cases and controls who participated in GWAS. It then correlated the imputed gene expression with traits to perform a TWAS and identified significant expression-trait associations. [@B35] have integrated gene expression measurements from 45 expression panels with 30 large-scale summary GWAS data to gain insight into the role of expression in the etiology of complex traits by using *TWAS*. We therefore included Mancuso's results into our study.

### Data-Driven Expression Prioritized Integration for Complex Traits {#S3.SS3.SSS8}

The *DEPICT* tool predicts the most likely causal genes by integrating GWAS and data and gene functions ([@B50]). Predefined gene sets and gene-transcriptional component matrix developed from gene expression data are used to obtain gene function. [@B65] have prioritized candidate causal genes for CAD using *DEPICT*. They defined sentinel SNPs as the most significant variant in a 1-Mb region that was independent from other sentinel SNPs (*r*^2^ \< 0.1), which was consistent with [@B50]. Therefore, we included Van der Harst's results ([@B65]) (prioritized causal gene list) into our study.

Ranking the Potential Causal Genes {#S3.SS4}
----------------------------------

We used eight different approaches to predict the potential causal genes of CAD. As they are complementary with each other, we assigned equal weights to all methods. Each candidate gene will receive a score of 1 if it is identified by any of the above-mentioned approaches. A cumulative scoring strategy was performed to rank the causal genes. For example, if a gene was only identified by *Sherlock* analysis, the total score of this gene was 1 point. If a gene was identified by both *Sherlock* and *SMR*, the total score of this gene was 2 points. The higher the score of a gene, the more consistent its evidence for identification across the methods and thus the greater the likelihood of involvement in disease susceptibility.

Gene Ontology and Kyoto Encyclopedia of Genes and Genomes Enrichment Analysis {#S3.SS5}
-----------------------------------------------------------------------------

We performed GO analysis to test if the identified potential causal genes were significantly enriched in specific functional categories by using DAVID ([@B22],[@B23]). Three GO terms, including biological process (BP), cellular component (CC), and molecular function (MF) were used. We also conducted KEGG enrichment analysis using ToppGene ([@B8]). KEGG pathways and GO terms with adjusted *P* values less than 0.05 \[Benjamini and Hochberg (BH) method for correction of multiple testing\] were considered as statistical significant.

Tissue-Specific Enrichment Analysis {#S3.SS6}
-----------------------------------

In order to identify the most relevant tissue for CAD candidate causal genes, we calculated a *pSI* score for each gene to represent its enrichment in a specific tissue. Details of *pSI* score calculation can refer to the original publication ([@B69]). For each tissue, genes with *pSI* \< 0.05 are considered as significantly enriched in the tissue. The overlap between CAD potential causal genes and the genes enriched in each tissue was estimated by Fisher's exact test. Bonferroni correction was used to adjust for multiple testing. The significant threshold was defined as *P* \< 0.002, because 25 tissues were tested.

Analysis of Protein--Protein Interaction and Co-Expression Network {#S3.SS7}
------------------------------------------------------------------

To explore the physical interaction among the proteins encoded by the potential causal genes, we used human PPI data from STRING ([@B61]). Additionally, we further investigated the co-expressed genes of the prioritized causal genes using GeneMANIA ([@B43]). Cytoscape was employed to visualize the network ([@B56]). We assumed that the gene association density of CAD potential causal gene set was higher than that of random gene sets. To test this hypothesis, we generated 1,000 random gene sets, each with the same number of genes as CAD potential causal gene set, and we assessed the significance using *Z*-test.

Pathway Crosstalk Analysis {#S3.SS8}
--------------------------

In order to explore the interactions among significantly enriched pathways, we further performed pathway crosstalk analysis. Two pathways were considered to crosstalk if they share a proportion of genes prioritized in our study. We employed two measurements to indicate the overlap of a pair of pathways: the Jaccard coefficient $\left( {{\text{JC};{JC}} = \frac{\left| {A \cap B} \right|}{\left| {A \cup B} \right|}} \right)$ and the overlap coefficient $\left( {{\text{OC};{OC}} = \frac{\left| {A \cap B} \right|}{\min\left( \left| A \right|,\left| B \right| \right)}} \right)$, where *A* and *B* represent the number of candidate genes in the two pathways. In order to preclude non-specific inclusion of crosstalk, we set up the following rules: (1) only pathways with adjusted *P* values \< 0.05 were included; (2) only pathways contained at least three candidate genes were included; and (3) pathway pairs with less than two overlapped candidate genes were removed. We visualized the results of pathway crosstalk analysis using Cytoscape ([@B56]).

Results {#S4}
=======

Potential Causal Genes Identified by *Sherlock* {#S4.SS1}
-----------------------------------------------

To identify genes whose expression level change may confer risk of CAD, we systematically integrated genetic associations from the largest GWAS of CAD so far with blood eQTL data from GTEx using *Sherlock*, a Bayesian statistical framework. We identified 17 potential causal genes whose expression level may affect CAD risk at *P* \< 8.7 × 10^--6^ (Bonferroni corrected *P* \< 0.05, [Supplementary Table S1](#DS1){ref-type="supplementary-material"}). For each gene, at least one SNP showed significant association with the expression of this gene and CAD risk simultaneously, implying that these SNPs may exert their effects through regulating gene expression.

Potential Causal Genes Identified by *SMR* {#S4.SS2}
------------------------------------------

We further utilized a different integrative analysis method, *SMR*, to identify CAD risk genes through integrating CAD GWAS and blood eQTL data from CAGE. *SMR* identified six genes at *P* \< 5.24 × 10^--6^. However, *VAMP8* and *MAT2A* did not pass *HEIDI* test (*P* \< 0.05), and only four genes (*PSRC1*, *LIPA*, *SWAP70*, and *NT5C2*) were retained ([Supplementary Table S2](#DS1){ref-type="supplementary-material"}). Intriguingly, three of them (*PSRC1*, *LIPA*, and *NT5C2*) were also identified by *Sherlock*, bringing further evidence to support that they might be the authentic risk genes for CAD.

Potential Causal Genes Identified by *DAPPLE* {#S4.SS3}
---------------------------------------------

Disease Association Protein--Protein Link Evaluator prioritizes disease-associated genes through using PPI data. A total of 58 genes were identified at corrected *P* \< 0.05 ([Supplementary Table S3](#DS1){ref-type="supplementary-material"}). The top prioritized genes included *SVEP1*, *APOB*, *FES*, *SLC22A4*, *PLG*, *ABCG5*, *FLT1*, *HNF1A*, *LDLR*, and *UBE2Z*. GO analysis showed that these prioritized genes were enriched in lipid metabolism, transportation, and storage-related pathways ([Supplementary Table S4](#DS1){ref-type="supplementary-material"}).

Potential Causal Genes Identified by *NetWAS* {#S4.SS4}
---------------------------------------------

We further mapped the gene-wide results to liver-specific network and classified by machine learning models as implemented by *NetWAS*. The top 50 genes were included in our further analysis ([Supplementary Table S5](#DS1){ref-type="supplementary-material"}). The most significant GO terms enriched among promising candidates genes were "protein binding" (corrected *P* = 7.6 × 10^--8^), "cytosol" (corrected *P* = 2.0 × 10^--7^), and "nucleoplasm" (corrected *P* = 4.3 × 10^--7^) ([Supplementary Table S6](#DS1){ref-type="supplementary-material"}).

Potential Causal Genes Identified by *Prix Fixe* {#S4.SS5}
------------------------------------------------

We further predicted CAD causal genes using *prix fixe*, which incorporates the functionally coherent subnetworks into network analysis. Ten genes were identified by *prix fixe*, including *PCSK9*, *DHCR24*, *SOD2*, *LPA*, *PLG*, *MAP3K4*, *CDKN2B*, *CDKN2A*, *ADORA2A*, and *DERL3* ([Supplementary Table S7](#DS1){ref-type="supplementary-material"}). Of note, *PCSK9* ranked the highest score among those genes. Genetic evidence indicated that individuals with inactivating mutations in *PCSK9* have decreased levels of circulating *LDL* and CAD risk, which led to the two monoclonal antibodies that inhibit *PCSK9* to be approved by the United States Food and Drug Administration ([@B11]). The finding of *PCSK9* further reinforced other genes identified by *prix fixe* as promising causal genes for CAD.

The Integrated Landscape of Causal Genes in Coronary Artery Disease {#S4.SS6}
-------------------------------------------------------------------

We utilized different approaches (including *Sherlock*, *SMR*, *DAPPLE*, *NetWAS*, *prix fixe*, *GWAB*, *DEPICT*, and *TWAS*) to prioritize the potential causal genes for CAD. In order to obtain the global landscape of plausible causal genes, we also integrated candidate causal genes identified by previous studies. Studies included in our further analysis are summarized as follows: (1) Causal genes predicted by Pavlides et al. using SMR ([@B49]). By integrating Westra blood eQTL data ([@B70]) and CARDIoGRAMplusC4D 1000 Genomes-based GWAS data (60,801 cases and 123,504 controls) ([@B47]), [@B49] used SMR to prioritize genes and identify five candidate genes (*VAMP8*, *SWAP70*, *IL6R*, *ATP5G1*, and *EIF2B2*) that passed both *SMR* and *HEIDI* test ([Supplementary Table S8](#DS1){ref-type="supplementary-material"}). (2) Causal genes predicted by *GWAB* ([@B57]). Jung Eun Shim et al. used GWAS data from CARDIoGRAMplusC4D consortium (22,233 cases and 64,762 controls) as input and references genes from three disease gene databases (OMIM, DO, and CADgeneDB) as benchmark to predict for disease-associated genes. After network boosting, 35 genes from the largest component of the network were significantly associated with CAD (GWAB score \> 7.3) ([Supplementary Table S9](#DS1){ref-type="supplementary-material"}). (3) Causal genes predicted by *DEPICT* ([@B65]). [@B19] predicted the causal genes for CAD recently. A total of 433 genes were identified as plausible candidate genes for CAD (FDR \< 0.01) ([Supplementary Table S10](#DS1){ref-type="supplementary-material"}). (4) Causal genes predicted by *TWAS*. [@B35] integrated CARDIoGRAM consortium GWAS data ([@B54]) with various expression panels and identified 12 genes significantly associated with CAD ([Supplementary Table S11](#DS1){ref-type="supplementary-material"}).

Given that the results of the eight analytical methods are correlated but not identical, genes genuinely involved in disease susceptibility would be expected to show consistent results across several methods. We therefore adopted the method of cumulative scoring strategy and ranked the plausible causal genes by their frequency of occurrences in the results of different approaches. We summarized the results in [Table 1](#T1){ref-type="table"} and generated the landscape of potential causal genes in CAD ([Figure 2](#F2){ref-type="fig"}). This yielded 55 candidate genes with total score ≥2, among which 15 genes were captured by at least three analysis methods. Therefore, these 15 genes (*LPL*, *COL4A2*, *PLG*, *CDKN2B*, *COL4A1*, *FES*, *FLT1*, *FN1*, *IL6R*, *LPA*, *PCSK9*, *PSRC1*, *SMAD3*, *SWAP70*, and *VAMP8*) were considered as the most promising causal genes for CAD. We queried the NHGRI-EBI GWAS Catalog ([@B5]) about the candidate genes to assess their potential pleiotropic effects. Notably, many of these genes provided evidence of pleiotropic effect of lipid traits, which confirmed the significant role of lipid metabolism in CAD.

###### 

Summary of 55 prioritized causal genes.

  No.   Gene         Locus      First identified by GWAS   Potential biological function                    Other related traits\*                                                                                                                                                                                                                                                     Methods
  ----- ------------ ---------- -------------------------- ------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------
  1     *LPL*        8p21.3     2017--2018                 Triglyceride-rich lipoproteins                   HDL, TG                                                                                                                                                                                                                                                                    Sherlock, GWAB, TWAS, DEPICT, DAPPLE
  2     *COL4A2*     13q34      2011                       Cellular proliferation and vascular remodeling   Colorectal cancer, coronary artery calcification, DBP, TC                                                                                                                                                                                                                  NetWAS, GWAB, DEPICT, DAPPLE
  3     *PLG*        6q26       2015                       Cellular proliferation and vascular remodeling   Blood protein measurement                                                                                                                                                                                                                                                  GWAB, DEPICT, DAPPLE, prix fixe
  4     *CDKN2B*     9p21.3     2007--2008                 Cellular proliferation and vascular remodeling   Cancer, heart failure, diabetes mellitus, stroke, atrial fibrillation, mortality                                                                                                                                                                                           TWAS, DEPICT, prix fixe
  5     *COL4A1*     13q34      2011                       Cellular proliferation and vascular remodeling   Arterial stiffness measurement, stroke                                                                                                                                                                                                                                     GWAB, DEPICT, DAPPLE
  6     *FES*        15q26.1    2017--2018                 Uncertain                                        SBP, DBP                                                                                                                                                                                                                                                                   Sherlock, DEPICT, DAPPLE
  7     *FLT1*       13q12.3    2017--2018                 Cellular proliferation and vascular remodeling   --                                                                                                                                                                                                                                                                         GWAB, DEPICT, DAPPLE
  8     *FN1*        2q35       2017--2018                 Coagulation                                      Blood protein, SBP, DBP                                                                                                                                                                                                                                                    GWAB, DEPICT, DAPPLE
  9     *IL6R*       1q21.3     2015                       Inflammation                                     C-reactive protein, rheumatoid arthritis                                                                                                                                                                                                                                   SMR (Pavlides), DEPICT, DAPPLE
  10    *LPA*        6q26       2011                       LDL cholesterol and lipoprotein (a)              Lipoprotein a, LDL, colorectal cancer                                                                                                                                                                                                                                      DEPICT, DAPPLE, prix fixe
  11    *PCSK9*      1p32.3     2015                       LDL cholesterol and lipoprotein (a)              LDL, TC                                                                                                                                                                                                                                                                    DEPICT, DAPPLE, prix fixe
  12    *PSRC1*      1p13.3     2007--2008                 LDL cholesterol and lipoprotein (a)              LDL, TC, HDL                                                                                                                                                                                                                                                               Sherlock, SMR, TWAS
  13    *SMAD3*      15q22.33   2015                       Cellular proliferation and vascular remodeling   Asthma, Crohn's disease, inflammatory bowel disease                                                                                                                                                                                                                        GWAB, DEPICT, DAPPLE
  14    *SWAP70*     11p15.4    2015                       Cellular proliferation and vascular remodeling   SBP, DBP                                                                                                                                                                                                                                                                   SMR, SMR (Pavlides), DEPICT
  15    *VAMP8*      2p11.2     2015                       Cellular proliferation and vascular remodeling   Prostate cancer                                                                                                                                                                                                                                                            SMR (Pavlides), DEPICT, DAPPLE
  16    *ABCG5*      2p21       2017--2018                 LDL cholesterol and lipoprotein (a)              TC, LDL                                                                                                                                                                                                                                                                    GWAB, DAPPLE
  17    *ABCG8*      2p21       2017--2018                 LDL cholesterol and lipoprotein (a)              TC, LDL                                                                                                                                                                                                                                                                    GWAB, DAPPLE
  18    *ABO*        9q34.2     2011                       Uncertain                                        TC, LDL, von Willebrand factor, hematocrit, hemoglobin, factor VIII, alkaline phosphatase, coagulation factor                                                                                                                                                              Sherlock, TWAS
  19    *ACAD10*     12q24.12   2013--2014                 Uncertain                                        Esophageal cancer                                                                                                                                                                                                                                                          GWAB, TWAS
  20    *ALDH2*      12q24.12   2013--2014                 Uncertain                                        Ischemic stroke, alcohol consumption, uric acid                                                                                                                                                                                                                            GWAB, DEPICT
  21    *APOA1*      11q23.3    2011                       Triglyceride-rich lipoproteins                   HDL                                                                                                                                                                                                                                                                        DEPICT, DAPPLE
  22    *APOB*       2p24.1     2017--2018                 LDL cholesterol and lipoprotein (a)              TC, LDL                                                                                                                                                                                                                                                                    DEPICT, DAPPLE
  23    *ARNTL*      11p15.3    2017--2018                 Uncertain                                        C-reactive protein, TC                                                                                                                                                                                                                                                     DEPICT, DAPPLE
  24    *ATXN2*      12q24.12   2013--2014                 Uncertain                                        PAD                                                                                                                                                                                                                                                                        GWAB, DEPICT
  25    *CABIN1*     22q11.23   --                         --                                               --                                                                                                                                                                                                                                                                         Sherlock, DEPICT
  26    *CETP*       16q13      2017--2018                 LDL cholesterol and lipoprotein (a)              HDL, LDL, TC, TG, alcohol drinking. BMI                                                                                                                                                                                                                                    DEPICT, DAPPLE
  27    *CXCL12*     10q11.21   2011                       Inflammation                                     White blood cell count, eosinophil count, erythrocyte count, schizophrenia                                                                                                                                                                                                 DEPICT, DAPPLE
  28    *EDNRA*      4q31.22    2015                       Vascular tone and nitric oxide signaling         Large artery stroke, pancreatic carcinoma, PAD, SBP, PP                                                                                                                                                                                                                    DEPICT, DAPPLE
  29    *EPOR*       19p13.2    --                         --                                               Erythropoietin                                                                                                                                                                                                                                                             TWAS, DEPICT
  30    *FURIN*      15q26.1    2017--2018                 Uncertain                                        SBP, DBP, ischemic stroke, schizophrenia                                                                                                                                                                                                                                   DEPICT, DAPPLE
  31    *GGCX*       2p11.2     2015                       Cellular proliferation and vascular remodeling   Eosinophil count                                                                                                                                                                                                                                                           Sherlock, DAPPLE
  32    *GIGYF2*     2q37.1     2017--2018                 Uncertain                                        Schizophrenia                                                                                                                                                                                                                                                              DEPICT, DAPPLE
  33    *HNRNPUL1*   19q13.2    --                         --                                               Heel bone mineral density                                                                                                                                                                                                                                                  NetWAS, DEPICT
  34    *ITGB5*      3q21.2     2017--2018                 Uncertain                                        SBP                                                                                                                                                                                                                                                                        DEPICT, DAPPLE
  35    *LDLR*       19p13.2    2011                       LDL cholesterol and lipoprotein (a)              LDL, TC, abdominal aortic aneurysm                                                                                                                                                                                                                                         DEPICT, DAPPLE
  36    *LIPA*       10q23.31   2011                       LDL cholesterol and lipoprotein (a)              --                                                                                                                                                                                                                                                                         Sherlock, SMR
  37    *MAP3K4*     6q26       --                         --                                               Blood protein                                                                                                                                                                                                                                                              DEPICT, prix fixe
  38    *MRAS*       3q22.3     2009--2010                 Inflammation                                     BMI, SBP                                                                                                                                                                                                                                                                   TWAS, DAPPLE
  39    *NOS3*       7q36.1     2015                       Vascular tone and nitric oxide signaling         SBP, DBP, stroke                                                                                                                                                                                                                                                           DEPICT, DAPPLE
  40    *NRP1*       10p11.22   2017--2018                 Uncertain                                        Migraine                                                                                                                                                                                                                                                                   NetWAS, DEPICT
  41    *NT5C2*      10q24.33   2011                       Uncertain                                        SBP, DBP, PP, BMI, schizophrenia, smoking behavior                                                                                                                                                                                                                         Sherlock, SMR
  42    *PEMT*       17p11.2    2011                       Uncertain                                        BMI, WHR                                                                                                                                                                                                                                                                   DEPICT, DAPPLE
  43    *PPAP2B*     1p32.2     2011                       LDL cholesterol and lipoprotein (a)              Reticulocyte count, heel bone mineral density                                                                                                                                                                                                                              DEPICT, DAPPLE
  44    *PTPN11*     12q24.13   2013--2014                 Uncertain                                        Eosinophil count, SBP, DBP, platelet count, reticulocyte count, smoking                                                                                                                                                                                                    GWAB, DEPICT
  45    *REST*       4q12       2017--2018                 Uncertain                                        Risk-taking behavior                                                                                                                                                                                                                                                       DEPICT, DAPPLE
  46    *RHOA*       3p21.31    2017--2018                 Uncertain                                        Cognitive function, self-reported educational attainment, intelligence                                                                                                                                                                                                     DEPICT, DAPPLE
  47    *RRBP1*      20p12.1    2017--2018                 Uncertain                                        Migraine, height                                                                                                                                                                                                                                                           NetWAS, DEPICT
  48    *SH2B3*      12q24.12   2015                       Inflammation                                     SBP, DBP, BMI, LDL, HDL, alcohol consumption, autoimmune disease, colorectal cancer, endometrial carcinoma, eosinophil count, eosinophil count, fibrinogen, hemoglobin, Ischemic stroke, leukocyte, lymphocyte, platelet, rheumatoid arthritis, type I diabetes mellitus   DEPICT, DAPPLE
  49    *SMG6*       17p13.3    2011                       Uncertain                                        BMI, bone density, schizophrenia, platelet, smoking                                                                                                                                                                                                                        DEPICT, DAPPLE
  50    *SOD2*       6q25.3     --                         --                                               Self-reported educational attainment, age at menopause                                                                                                                                                                                                                     DEPICT, prix fixe
  51    *SVEP1*      9q31.3     2017--2018                 Uncertain                                        Bipolar disorder, SBP                                                                                                                                                                                                                                                      DEPICT, DAPPLE
  52    *TGFB1*      19q13.2    2017--2018                 Uncertain                                        T2D                                                                                                                                                                                                                                                                        DEPICT, DAPPLE
  53    *TRIB1*      8q24.13    2017--2018                 Triglyceride-rich lipoproteins                   HDL, LDL, TG, glomerular filtration rate                                                                                                                                                                                                                                   DEPICT, DAPPLE
  54    *UBE2Z*      17q21.32   2011                       Uncertain                                        Educational attainment, T2D                                                                                                                                                                                                                                                DEPICT, DAPPLE
  55    *ZEB2*       2q22.3     2015                       Uncertain                                        Renal cell carcinoma, schizophrenia, self-reported educational attainment                                                                                                                                                                                                  DEPICT, DAPPLE

\*The association with other traits or diseases was identified from the National Human Genome Research Institute-European Bioinformatics Institute GWAS catalog. LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglyceride; DBP, diastolic blood pressure; SBP, systolic blood pressure; TC, total cholesterol; PAD, peripheral arterial disease; PP, pulse pressure; BMI, body mass index; WHR, waist--hip ratio; T2D, type 2 diabetes.

![Top causal genes identified in this study.](fgene-11-00320-g002){#F2}

To identify the biological roles of the 55 potential causal genes, we performed GO enrichment analysis using DAVID. We found that candidate genes were significantly enriched in the GO term such as cholesterol homeostasis (corrected *P* \< 9.6 × 10^--7^), lipoprotein metabolic process (corrected *P* \< 5.1 × 10^--5^), receptor complex (corrected *P* \< 2.5 × 10^--4^), cholesterol transporter activity (corrected *P* \< 2.6 × 10^--5^), extracellular region (corrected *P* \< 6.8 × 10^--3^), and apolipoprotein binding (corrected *P* \< 1.2 × 10^--3^) ([Figure 3](#F3){ref-type="fig"}). These results indicated that lipid metabolic and extracellular region might play a critical role in the pathophysiology of CAD.

![Gene Ontology enrichment analysis of the prioritized causal genes of CAD.](fgene-11-00320-g003){#F3}

We then examined the most relevant tissue of CAD potential causal genes using tissue-specific enrichment analysis. As shown in [Figure 4](#F4){ref-type="fig"}, these genes tended to be significantly overexpressed in liver (*P* = 2.2 × 10^--6^) and adipose tissue (*P* = 2.8 × 10^--7^). Considering genes are usually act synergistically to exert their biological function, also called as "guilt by association" principle, we further performed network analysis using PPI and expression data. As shown in [Figure 5](#F5){ref-type="fig"}, genes in the PPI network ([Figure 5A](#F5){ref-type="fig"}) and co-expression network ([Figure 5B](#F5){ref-type="fig"}) demonstrated more interaction among themselves than what would be expected for a random set of genes of the same size (*P* \< 1.0 × 10^--16^). Dysregulation of any gene in this highly interconnected network will affect the function of the network, which eventually lead to pathogenesis of CAD.

![Tissue-specific expression enrichment of CAD potential causal genes. The 53 tissues in GTEx were grouped into 25 broad tissue types. The size of the hexagon was scaled to the number of genes meeting the *pSI* threshold, and its color indicates results of Fisher's exact test.](fgene-11-00320-g004){#F4}

![Top causal genes encoded a densely interconnected PPI **(A)** and co-expression **(B)** network.](fgene-11-00320-g005){#F5}

Kyoto Encyclopedia of Genes and Genomes Enrichment Analysis and Pathway Crosstalk Analysis {#S4.SS7}
------------------------------------------------------------------------------------------

Identifying KEGG pathways enriched in the candidate genes may provide further insight of the molecular mechanisms related to CAD. [Table 2](#T2){ref-type="table"} shows the 24 significant enriched pathways. Among these, the top five pathways are fat digestion and absorption (*P*~BH~ = 6.63 × 10^--5^), AGE-RAGE signaling pathway in diabetic complications (*P*~BH~ = 1.92 × 10^--4^), pathways in cancer (*P*~BH~ = 1.12 × 10^--3^), PI3K-Akt signaling pathway (*P*~BH~ = 1.90 × 10^--3^), and focal adhesion (*P*~BH~ = 3.96 × 10^--3^).

###### 

KEGG enrichment analysis in CAD prioritized causal genes.

  Pathway                                                ID         *P* value        *P*~BH~ value    Candidate genes in the pathway
  ------------------------------------------------------ ---------- ---------------- ---------------- ----------------------------------------------------------------------------------
  Fat digestion and absorption                           hsa04975   5.72 × 10^--7^   6.63 × 10^--5^   *PLPP3*, *APOA1*, *APOB*, *ABCG5*, *ABCG8*
  AGE-RAGE signaling pathway in diabetic complications   hsa04933   2.60 × 10^--6^   1.92 × 10^--4^   *TGFB1*, *COL4A1*, *COL4A2*, *FN1*, *NOS3*, *SMAD3*
  Pathways in cancer                                     hsa05200   2.35 × 10^--5^   1.12 × 10^--3^   *TGFB1*, *COL4A1*, *RHOA*, *COL4A2*, *CDKN2B*, *FN1*, *CXCL12*, *EDNRA*, *SMAD3*
  PI3K-Akt signaling pathway                             hsa04151   5.86 × 10^--5^   1.90 × 10^--3^   *COL4A1*, *COL4A2*, *EPOR*, *FLT1*, *FN1*, *ITGB5*, *NOS3*, *IL6R*
  Focal adhesion                                         hsa04510   1.37 × 10^--4^   3.96 × 10^--3^   *COL4A1*, *RHOA*, *COL4A2*, *FLT1*, *FN1*, *ITGB5*
  Proteoglycans in cancer                                hsa05205   1.53 × 10^--4^   4.10 × 10^--3^   *TGFB1*, *RHOA*, *PTPN11*, *MRAS*, *FN1*, *ITGB5*
  ECM-receptor interaction                               hsa04512   3.20 × 10^--4^   6.30 × 10^--3^   *COL4A1*, *COL4A2*, *FN1*, *ITGB5*
  Small cell lung cancer                                 hsa05222   3.51 × 10^--4^   6.32 × 10^--3^   *COL4A1*, *COL4A2*, *CDKN2B*, *FN1*
  TGF-beta signaling pathway                             hsa04350   3.51 × 10^--4^   6.32 × 10^--3^   *TGFB1*, *RHOA*, *CDKN2B*, *SMAD3*
  Amebiasis                                              hsa05146   5.83 × 10^--4^   9.45 × 10^--3^   *TGFB1*, *COL4A1*, *COL4A2*, *FN1*
  Axon guidance                                          hsa04360   6.58 × 10^--4^   1.03 × 10^--2^   *RHOA*, *PTPN11*, *FES*, *CXCL12*, *NRP1*
  Glycerolipid metabolism                                hsa00561   1.69 × 10^--3^   1.99 × 10^--2^   *PLPP3*, *LPL*, *ALDH2*
  Colorectal cancer                                      hsa05210   1.78 × 10^--3^   2.06 × 10^--2^   *TGFB1*, *RHOA*, *SMAD3*
  FoxO signaling pathway                                 hsa04068   1.91 × 10^--3^   2.06 × 10^--2^   *TGFB1*, *CDKN2B*, *SMAD3*, *SOD2*
  Phospholipase D signaling pathway                      hsa04072   2.75 × 10^--3^   2.45 × 10^--2^   *RHOA*, *PTPN11*, *MRAS*, *PLPP3*
  Bile secretion                                         hsa04976   2.88 × 10^--3^   2.48 × 10^--2^   *LDLR*, *ABCG5*, *ABCG8*
  Chronic myeloid leukemia                               hsa05220   2.88 × 10^--3^   2.48 × 10^--2^   *TGFB1*, *PTPN11*, *SMAD3*
  HTLV-I infection                                       hsa05166   3.52 × 10^--3^   2.80 × 10^--2^   *TGFB1*, *CDKN2B*, *MRAS*, *SMAD3*, *NRP1*
  Endocytosis                                            hsa04144   3.76 × 10^--3^   2.85 × 10^--2^   *TGFB1*, *RHOA*, *FLT1*, *LDLR*, *SMAD3*
  phosphatidylcholine (PC) biosynthesis, PE → PC         hsa00091   4.03 × 10^--3^   2.92 × 10^--2^   *PEMT*
  Vitamin digestion and absorption                       hsa04977   4.12 × 10^--3^   2.93 × 10^--2^   *APOA1*, *APOB*
  Cytokine--cytokine receptor interaction                hsa04060   4.42 × 10^--3^   3.11 × 10^--2^   *TGFB1*, *EPOR*, *FLT1*, *IL6R*, *CXCL12*
  Rheumatoid arthritis                                   hsa05323   5.60 × 10^--3^   3.69 × 10^--2^   *TGFB1*, *FLT1*, *CXCL12*
  HIF-1 signaling pathway                                hsa04066   7.71 × 10^--3^   4.77 × 10^--2^   *FLT1*, *NOS3*, *IL6R*

In order to gain deep understanding of how these pathways are related, we further performed a pathway crosstalk analysis. There were 22 pathways containing at least three candidate genes and met the inclusion criteria for crosstalk analysis. A total of 73 edges connected between any two of these pathways, and these edges represented the overlapping level, which was measured according to the average score of JC and OC. As shown in [Figure 6](#F6){ref-type="fig"}, the largest crosstalk module comprised 20 pathways. By considering the topological characteristics, we identified five key pathways (pathways in cancer, AGE-RAGE signaling pathway in diabetic complications, proteoglycans in cancer, endocytosis, and PI3K-Akt signaling pathway), which had the highest betweenness centrality and degree value ([Supplementary Table S12](#DS1){ref-type="supplementary-material"}). Previous studies had provided some clues about their role in pathogenesis of CAD ([@B9]; [@B26]; [@B29]).

![Crosstalk network among CAD prioritized causal genes enriched pathways. In this figure, each node represents a pathway, and each edge represents crosstalk between pathways. The color of each node is proportional to the adjusted *P* \[Benjamini and Hochberg (BH) method\] value. Darker color represents lower *P*~BH~ value. The size of each node is proportional to the number of CAD prioritized causal genes in the corresponding pathway. The width of each edge is proportional to the mean value of the two coefficients (JC and OC). Larger edge width represents higher proportion of overlap between pathways.](fgene-11-00320-g006){#F6}

Discussion {#S5}
==========

Although 163 loci have now been associated with CAD at a genome-wide level of significance ([@B13]), the reported loci usually span a large chromosomal region and contain many genes. Thus, it is difficult to pinpoint the causal gene. Besides, owing to the complexity of gene regulatory and LD pattern, this problem becomes even more complicated. Consequently, incorporating other source of prior knowledge is necessary to narrow down the CAD candidate genes. In this study, we conducted a comprehensive integrative analysis and prioritized the potential causal genes for CAD using the latest GWAS and other omics data from different layers. A total of 55 plausible causal genes were identified, among which 15 genes ranked the highest priority because of their consistent evidence from different data-driven approaches. Many of these genes were involved in in lipid metabolic and extracellular related BP. Moreover, they were enriched in liver and adipose tissue. Further, KEGG and crosstalk analysis also revealed several key pathways participating in the pathogenesis of CAD.

Our comprehensive analysis predicted 55 CAD causal genes. Many of these genes are well-known CAD driver genes and participant in lipid metabolic process (*LPL*, *LPA*, *PCSK9*, *APOA1*, *APOB*, *CETP*, *LDLR*, and *LIPA*). Some of them have been translated into the targets of commercialized drugs (*APOB* and *PCSK9*). Besides, GO enrichment analysis also highlight the importance of lipid involved in CAD pathogenesis. However, targeting novel pathways instead of established CAD risk factors, such as lipid levels, may facilitate the drug development and catalyze novel CAD therapeutic options. Our GO analysis also pinpointed that the identified potential causal genes were enriched in extracellular region apart from lipid metabolic. Extracellular matrix has a critical role in cell adhesion, integrity, and communication. Changes in the extracellular space have been implicated in the pathogenesis of atherosclerosis and restenosis ([@B10]). Previous network analysis also revealed the key role of extracellular region involved in CAD development and the relationship between other molecular mechanisms, such as inflammatory response and complement and coagulation ([@B72]).

In addition to identifying the well-known CAD driver genes, our comprehensive analysis also detected novel or less well-studied plausible causal genes for CAD. For example, *MAP3K4* encodes Mitogen-Activated Protein Kinase 4, which is the central core of each mitogen-activated protein (MAP) kinase pathway. Four well-characterized MAP kinase pathways, including ERK1/2, JNK, p38, and ERK5, have been reported their role in different aspects of cardiac regulation, from development to pathological remodeling ([@B67]). In line with our study, [@B1] analyzed CARDIoGRAMplusC4D GWAS data by *Gentrepid* and found that *MAP3K4* was one of the possible causal genes of CAD. Another candidate, *CABIN1*, plays a pivotal role in the T cell receptor-mediated signal transduction pathway and inhibits calcineurin-mediated signal transduction. Calcineurin lies at the intersection of protein phosphorylation and calcium signaling cascades and contributes to pathological hypertrophic remodeling ([@B32]; [@B48]). Another identified gene, *EPOR*, encodes erythropoietin (EPO) receptor. EPO has shown its effect beyond hematopoiesis, such as suppression of atherosclerosis ([@B64]) and prevention of cardiac apoptosis ([@B45]). In addition, although EpoR agonists drugs are initially aimed at treating anemia, it is starting to demonstrate the sign of pleiotropic effects for treating a wide range of complex disorders, including CVD, neurodegenerative disorders, spinal cord injury, and diabetic retinopathy ([@B52]). *HNRNPUL1* encodes a nuclear RNA-binding protein and involved in mRNA splicing pathway. [@B31] integrated GWAS data of CAD and several CVD risk factors and used a shared polygenic signal-informed statistical framework to discover novel CAD genes. Totally, they identified 67 novel loci associated with CAD. Among these novel loci, rs12459996 near *CYP2F1* also showed eQTL effect on *HNRNPUL1* gene expression in blood tissue (*P* = 3.86 × 10^--16^), which indicated that this locus may exert its effect on CAD susceptibility through regulation of *HNRNPUL1* expression. Superoxide Dismutase 2 (*SOD2*) is a well-known marker of endothelial dysfunction. Several candidate gene studies have revealed that mutations or polymorphisms of *SOD2* gene are associated with CAD risk ([@B42]; [@B63]). Moreover, studies on Sod2-deficient mice demonstrated accelerated atherosclerosis ([@B73]) and atherosclerotic plaque instability ([@B66]). These lines of evidence suggested that *SOD2* might act an important role in CAD pathogenesis by regulating atherosclerosis and endothelial function.

Pathway enrichment analysis of the prioritized genes further confirmed some results of previous studies. Some key drivers of CAD identified by previous network analysis were cancer-related genes ([@B72]). Although recognized as two separate diseases, CAD and cancer possess various similarities, from common risk factors to shared BP ([@B29]). The oxidative stress and chronic inflammation underlie both of the diseases. In addition, a growing number of evidence support a role for statins, angiotensin-converting enzyme inhibitor/angiotensin receptor blockers (ACEIs/ARBs), and aspirin in cancer prevention ([@B36]). Anti-CD47 antibody treatment may become a novel therapeutic strategy for CAD by promoting efferocytosis ([@B30]). This convergent evidence indicated that pathways of cancer might take part in the pathogenesis of CAD. AGE-RAGE signaling pathway actively participates in inflammation and immune response. [@B39] identified 413 differential expressed genes from two gene expression datasets of CAD cases and healthy controls, and they highlighted the role of AGE-RAGE signaling pathway in CAD pathogenesis. Extensive evidence is building to implicate AGE-RAGE in the pathogenesis of vascular perturbation, which stimulate processes that lead to the development of arterial stiffness ([@B55]). AGE/RAGE signaling also demonstrated its role in diabetes-mediated vascular calcification ([@B26]). Calcium deposits in coronary arteries may weaken vasomotor responses and alter atherosclerotic plaque stability ([@B33]). Another two well-known pathways identified in our study were focal adhesion (hsa04510) and PI3K-Akt signaling pathway (hsa04151). Focal adhesion has an influence on both leucocyte motility within intima and interactions between platelets and endothelium through controlling cytoskeletal or adhesion dynamics ([@B7]). [@B6] employed integrative pathway and network analysis and revealed that focal adhesion was one of the shared molecular pathways for CAD and diabetes across diverse ethnicities. The PI3K-Akt pathway has been reported involved in cell proliferation, survival, and apoptosis. A two-stage systems genetics analysis of CAD GWAS data also found convincing association between PI3K-Akt pathway and CAD ([@B16]). Crosstalk analysis further demonstrated that these pathways might interconnect through overlapping genes instead of acting alone. Therefore, disruption or dysfunction of any key genes in the network may have cascading effects and result in a series of functional pathological consequences.

Our study is different from traditional fine-mapping approaches, which focus on identifying the causal variants that affect a trait of interest. Although very important, knowing which variants are causal does not equal to identifying the downstream effects of the variant on the trait. Moreover, if the causal genes affected by a locus are known, this can reduce the credible set of potential causal variants ([@B53]; [@B4]). Therefore, recent efforts in systems biology, integrating GWAS data and *a priori* knowledge from other omics, have focused on identifying such causal genes.

Unlike previous study ([@B3]; [@B40]), which only focused on genome-wide significant region to predict causal genes, our study predicted plausible causal genes for CAD at genome-wide level by using genetic variants of both strong and subtle effects. Besides, to our knowledge, this is the first systematic analysis for CAD using comprehensive data from different layers to prioritize candidate genes. However, this study has several potential limitations. First, our study only paid attention to those genes that were prioritized by at least two computational methods. This strategy may omit some authentic CAD susceptibility genes. Besides, we assigned these methods with equal weights when combining the results. There might exist some discrepancies among the various methods because of different rationales and datasets. Further studies are needed to search the optimum weights. Second, we used eQTL data from peripheral blood samples when we conduced *Sherlock* and *SMR* analyses. Although blood tissue can be a proxy for eQTL effect in various diseases, it might be not ideal because we certainly lose power for eQTLs with tissue-specific effects ([Supplementary Table S13](#DS1){ref-type="supplementary-material"}). However, we gain power for genes with consistent effects across tissues because of the use of a very large sample size for eQTL analysis in blood. Future studies using large-scale eQTL data in pathophysiologically relevant tissues are needed to validate our results. Third, we did not consider other QTLs from different omic layers, such as DNA methylation (meQTLs), protein (pQTLs), or metabolites (mQTLs), which limited our ability to study from multi-omics perspective. In addition, the statistical methods did not perform causal inference; therefore, the genes identified in our study were only plausible candidate causal genes. However, the results still played a pivotal role in prioritizing genes for experimental follow-up. Further studies are needed to validate our results and elucidate the biological mechanisms.

Conclusion {#S6}
==========

In summary, we integrated multi-dimensional data and depicted the landscape of plausible candidate causal genes for CAD. GO analysis further showed that these genes were enriched in lipid metabolism and extracellular region. Tissue-specific enrichment analysis revealed that these genes were significantly overexpressed in adipose and liver tissues. Further studies and experimental validations of these genes may shed light on mechanistic insights into CAD pathogenesis and provide potential drug targets for future therapeutics.
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CAD

:   coronary artery disease

CVD

:   cardiovascular disease
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:   Disease Association Protein--Protein Link Evaluator
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:   Data-Driven Expression Prioritized Integration for Complex Traits

eQTL

:   expression quantitative trait locus

FDR

:   false discovery rate
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:   Genotype-Tissue Expression

GWAB

:   Genome-Wide Association Boosting

GWAS

:   genome-wide association study

KEGG

:   Kyoto Encyclopedia of Genes and Genomes
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:   linkage disequilibrium
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:   Network-Wide Association Study
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:   protein--protein interaction
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:   summary data-based Mendelian randomization
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:   transcriptome-wide association studies.
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